RAPT Therapeutics, Inc. (RAPT) Net Cash Flow (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Net Cash Flow for 5 consecutive years, with $131.8 million as the latest value for Q4 2024.
- Quarterly Net Cash Flow rose 2080.4% to $131.8 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $122.3 million through Dec 2024, up 1332.92% year-over-year, with the annual reading at $122.3 million for FY2024, 1332.92% up from the prior year.
- Net Cash Flow hit $131.8 million in Q4 2024 for RAPT Therapeutics, up from $823000.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $131.8 million in Q4 2024 to a low of -$62.6 million in Q2 2020.
- Historically, Net Cash Flow has averaged $4.6 million across 5 years, with a median of $2.4 million in 2023.
- Biggest five-year swings in Net Cash Flow: plummeted 867.16% in 2021 and later skyrocketed 4337.88% in 2022.
- Year by year, Net Cash Flow stood at $4.7 million in 2020, then tumbled by 867.16% to -$36.0 million in 2021, then surged by 131.25% to $11.2 million in 2022, then tumbled by 159.23% to -$6.7 million in 2023, then soared by 2080.4% to $131.8 million in 2024.
- Business Quant data shows Net Cash Flow for RAPT at $131.8 million in Q4 2024, $823000.0 in Q3 2024, and -$8.2 million in Q2 2024.